PHASE III--PLATINUM COMPOUND AND PACLITAXEL IN EPITHELIAL OVARIAN CARCINOMA

卵巢癌患者的存活率相对保持不变。 在过去的20年里是不变的。直到最近，环磷酰胺和顺铂 被认为是晚期上皮癌患者的标准治疗方法 卵巢癌。然而，根据谷歌的一项研究，紫杉醇和顺铂 已经成为新的标准养生法。另一项GOG研究(试点)， 揭示了紫杉醇和卡铂的联合应用是一种有效的 方案，毒性是可以接受的，化疗耐受性良好 病人。这项目前的研究将解决输液时间的问题 紫杉醇。

Survival for patients with ovarian cancer has remained relatively constant for the last 20 years. Until recently, Cytoxan and cisplatin was considered to be standard therapy for patients with advanced epithelial ovarian cancer. However, based on a GOG study, paclitaxel and cisplatin has become the new standard regimen. Another GOG study (a pilot), revealed that the combination of paclitaxel and carboplatin was an active regimen, toxicity was acceptable and the chemo was well tolerated by patients. This current study will address the issue of infusion time for paclitaxel.